MM-003: Phase III Study of Pomalidomide and Low-Dose Dexamethasone versus High-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma


MM-003: Phase III Study of Pomalidomide and Low-Dose Dexamethasone versus High-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma
Slides from presentations at ASCO 2013/EHA 2013 and transcribed comments from a recent interview with Antonio Palumbo, MD (8/20/13)
San Miguel JF et al. MM-003: A Phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM). Proc ASCO 2013;Abstract 8510.

Weisel KC et al. Efficacy, safety, and QoL in MM-003, a Phase 3, multicenter, randomized, open-label study of pomalidomide (POM) + low-dose dexamethasone (LoDEX) vs high-dose dexamethasone (HiDEX) in RRMM. Proc EHA 2013;Abstract S1151.

Dr Palumbo is Chief of the Myeloma Unit in the University of Torino’s Division of Hematology in Torino, Italy.